← Back to Search

Other

Meibomian Gland Probing for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

N/A

Waitlist Available

Research Sponsored by Massachusetts Eye and Ear Infirmary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be adults (18 years of age or older)

Patients must have evidence of Meibomitis

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial will study the effects of meibomian gland expression on people with SJS/TEN. The primary outcome is meibography, and the secondary outcome is patient symptoms. The investigators hypothesize that meibomian gland expression will improve symptoms in those patients.

Who is the study for?

Adults over 18 with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) who are in the sub-acute phase (within 6 months of onset) and have meibomitis can participate. Those under 18, past the sub-acute phase, without meibomitis, or with unconfirmed SJS vs. other conditions cannot join.Check my eligibility

What is being tested?

The trial is testing if mechanically expressing meibomian glands improves eyelid disease and ocular surface health for patients in the early stages of SJS/TEN. Health will be measured by imaging gland caliber before and after treatment, plus a follow-up at six months.See study design

What are the potential side effects?

Potential side effects may include discomfort during mechanical expression of glands, temporary eye irritation or redness post-treatment. Specific side effect risks will depend on individual patient reactions to the procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with Meibomitis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Meibomian gland imaging (Meibography) - Qualitative description

Secondary outcome measures

Ocular Surface Disease Index survey

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Massachusetts Eye and Ear InfirmaryLead Sponsor

106 Previous Clinical Trials

12,919 Total Patients Enrolled

1 Trials studying Toxic Epidermal Necrolysis

Media Library

Meibomian Gland Probing (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05145959 — N/A

Toxic Epidermal Necrolysis Research Study Groups:

Toxic Epidermal Necrolysis Clinical Trial 2023: Meibomian Gland Probing Highlights & Side Effects. Trial Name: NCT05145959 — N/A

Meibomian Gland Probing (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05145959 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being invited to join this research project?

"Affirmative. Information available on clinicaltrials.gov indicates that this medical trial, posted in December 2021 and last updated in November 2021, is currently enrolling participants. A total of 30 patients are needed from a single site."

Answered by AI

Is this trial recruiting participants at the moment?

"As per the information accessible on clinicaltrials.gov, this research project is open for recruitment and has been since it was first publicised on December 1st 2021 with last revision made on November 23rd of that same year."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Hajirah N. Saeed, M.D. 2021. "Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05145959.